Wikisage, the free encyclopedia of the second generation, is digital heritage
Diacomit: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 5: | Line 5: | ||
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union | In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union | ||
Dravet Syndrome does not exist data | Dravet Syndrome does not exist data for combined therapy both valproic acid or cloabazam<ref>Aras et al 2015</ref> | ||
== | ==ATC== | ||
http://www.whocc.no/atc_ddd_index/?code=N03AX17 | http://www.whocc.no/atc_ddd_index/?code=N03AX17 | ||
<references/> | <references/> | ||
Revision as of 18:59, 31 March 2016
Diacomit contains 250 mg stiripentol[1]
-Stiripentol_Structural_Formulae_V.1.svg.png)
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
Dravet Syndrome does not exist data for combined therapy both valproic acid or cloabazam[2]